Rodríguez BS, Almeida GJ

Language: Spanish
References: 23
Page: 126
PDF size: 272.64 Kb.

Text Extraction

To the Editor:
We read with interest the article by Drs Gómez Recio and Lázaro García1 published in CorSalud, and do not agree with their approach because of the controversy on this issue, which is why the following comments are issued.

REFERENCES

1. Gómez Recio M, Lázaro García R. Por qué usar pre-ferentemente stents no farmacoactivos. CorSalud [Internet]. 2013 [Citado 2013 Nov 11];5(4):321-324. Disponible en:

2. http://www.corsalud.sld.cu/pdf/2013/v5n4a13/es/bms.pdf

3. Atary JZ, van der Hoeven BL, Liem SS, Jukema JW, van der Bom JG, Atsma DE, et al. Three-year out-come of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocar-dial infarction (from the MISSION! Intervention Study). Am J Cardiol. 2010;106(1):4-12.

4. Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial in-farction) trial. J Am Coll Cardiol. 2010;55(8):810-4.

5. Di Lorenzo E, Sauro R, Varricchio A, Capasso M,

6. Lanzillo T, Manganelli F, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009;158(4): e43-50.

7. de la Torre Hernández JM, Díaz Fernández JF, Saba-té Tenas M, Goicolea Ruigómez J. Actualización en cardiología intervencionista. Rev Esp Cardiol. 2012; 65(Supl. 1):4-11.

8. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv. 2011;4(1):24-9.

9. Piccolo R, Cassese S, Galasso G, De Rosa R, D'Anna C, Piscione F. Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. Atherosclerosis. 2011;217(1):149-57.

10. Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(8):977-87.

11. Wallace EL, Abdel-Latif A, Charnigo R, Moliterno DJ, Brodie B, Matnani R, et al. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(7):932-40.

12. 10.De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172(8):611-21.

13. 11.Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. JACC Cardiovasc Interv. 2012;5(3):313-22.

14. 12.Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62(6):496-504.

15. 13.Lindefjeld DS, Guarda E, Méndez M, Martínez A, Pérez O, Fajuri A, et al. Microvascular coronary flow comparison in acute myocardial infarction angio-plasty treated with a mesh covered stent (MGUARD stent) versus bare metal stent: MICAMI-MGUARD. Cardiovasc Revasc Med. 2013;14(1):4-8.

16. 14.Costa JR, Abizaid A, Dudek D, Silber S, Leon MB, Stone GW. Rationale and design of the MGuard for

17. acute ST elevation reperfusion MASTER trial. Cathe-ter Cardiovasc Interv. 2013;82(2):184-90.

18. 15.Sciahbasi A, Pendenza G, Golino L, Romagnoli E, Ca-ferri G, Patrizi R, et al. Closed versus open cell stent for high-risk percutaneous coronary interventions in ST-elevation acute myocardial infarction: the Closed versus Open Cells stent for High risk percu-taneous coronary Interventions in ST-Elevation acute myocardial infarction (COCHISE) pilot study. Am Heart J. 2013;165(3):415-20.

19. 16.Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59(23): 2051-7.

20. 17.Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yaz-dani SK, Ladich E, et al. The pathology of neoathe-rosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011; 57(11):1314-22.

21. 18.Vink MA, Dirksen MT, Tijssen JG, Suttorp MJ, Patterson MS, van Geloven N, et al. Lack of long-term clinical benefit of thrombus aspiration during primary percutaneous coronary intervention with paclitaxel-eluting stents or bare-metal stents: post-hoc analysis of the PASSION-trial. Catheter Cardio-vasc Interv. 2012;79(6):870-7.

22. 19.Escaned J, Echavarría-Pinto M, Gorgadze T, Gonzalo N, Armengol F, Hernández R, et al. Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction. EuroIntervention. 2013;8(10):1149-56.

23. 20.Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, et al. Intracoronary abcixi-mab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307(17):1817-26.